daptomycin | CMAC

Daptomycin in the treatment of infective endocarditis

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):35-40

10.36488/cmac.2018.1.35-40

This review characterizes daptomycin as a highly effective lipopeptide antibiotic being active against Gram-positive microorganisms, including multidrug resistant strains. The data reflecting the up-to-date daptomycin-based approaches to …

Evidence Based Review on Daptomycin Use in the Treatment of Gram(+) Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(4):270-281

Daptomycin is the only clinically used member of a cyclic lipopeptides class of antibiotics. Daptomycin has rapid bactericidal activity against not only rapidly growing, but also against slow growing bacterial cells including those in biofilms. …

Daptomycin – the Review of Pharmacological, Clinical and Microbiological Characteristics

Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(4):295-313

Daptomycin is the first approved member of a cyclic lipopeptides class of antibiotics with anti-Gram(+) activity. In contrast to majority of other antimicrobials daptomycin has rapid bactericidal activity against not only rapidly growing, but also …

Comparative Pharmacodynamics of Daptomycin and Vancomycin with Staphylococcus aureus in an in vitro Dynamic Model

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):186-192

To compare the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN) as well as killing kinetics of S. aureus with different MICs were studied at widely ranged AUC/MIC ratios. Two clinical isolates, S. aureus 866 (MICDAP 0.35 µ/ml and MICVAN 0.70 …